Advances in mesenchymal stem cell-mediated gene therapy for cancer

Stem Cell Research and Therapy

Volumn 1, Issue 3, 2010, Pages

  Dwyer, Roisin M ^a   Khan, Sonja ^a   Barry, Frank P ^a   O'Brien, Timothy ^a   Kerin, Michael J ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

5' NUCLEOTIDASE; CD14 ANTIGEN; CD19 ANTIGEN; CD34 ANTIGEN; CD45 ANTIGEN; CHEMOKINE RECEPTOR CCR10; CHEMOKINE RECEPTOR CCR9; CHEMOKINE RECEPTOR CX3CR1; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR5; CHEMOKINE RECEPTOR CXCR6; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYTOSINE DEAMINASE; DOXYCYCLINE; ENDOGLIN; GANCICLOVIR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; INTERLEUKIN 12; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; STROMAL CELL DERIVED FACTOR 1; STROMAL CELL DERIVED FACTOR 1ALPHA; THY 1 ANTIGEN; THYMIDINE KINASE; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UROKINASE;

ADIPOCYTE; ANTIGEN EXPRESSION; APOPTOSIS; CANCER GENE THERAPY; CARCINOGENESIS; CARTILAGE CELL; CELL DIFFERENTIATION; CELL HOMING; CELL LINEAGE; CELL MIGRATION; CELL RENEWAL; CELL SURFACE; HUMAN; IMMUNOPHENOTYPING; MESENCHYMAL STEM CELL; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; OSTEOBLAST; PRIORITY JOURNAL; PROTEIN SECRETION; REVIEW; SUBCUTANEOUS TISSUE TUMOR; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR VOLUME;

CELL- AND TISSUE-BASED THERAPY; DRUG DELIVERY SYSTEMS; GENE TRANSFER TECHNIQUES; HUMANS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; NEOPLASMS;

EID: 79952536557     PISSN: None     EISSN: 17576512     Source Type: Journal    
DOI: 10.1186/scrt25     Document Type: Review

References (79)

1. Multilineage potential of adult human mesenchymal stem cells. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR, Science 1999 284 143 147 10.1126/science.284.5411.143 10102814 (Pubitemid 29282067)
2. Mesenchymal stem cells: clinical applications and biological characterization. Barry FP, Murphy JM, Int J Biochem Cell Biol 2004 36 568 584 10.1016/j.biocel.2003.11.001 15010324 (Pubitemid 38324589)
3. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop D, Horwitz E, Cytotherapy 2006 8 315 317 10.1080/14653240600855905 16923606 (Pubitemid 44269669)
4. The (in) auspicious role of mesenchymal stromal cells in cancer: be it friend or foe. Kidd S, Spaeth E, Klopp A, Hall B, Marini FC, Cytotherapy 2008 10 657 667 10.1080/14653240802486517 18985472
5. Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Studeny M, Marini FC, Champlin RE, Zompetta C, Fidler IJ, Cancer Res 2002 62 3603 3608 12097260 (Pubitemid 34728832)
6. Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Nakamizo A, Marini F, Amano T, Khan A, Studeny M, Gumin J, Chen J, Hentschel S, Vecil G, Dembinski J, Lang FF, Cancer Res 2005 65 3307 3318 15833864 (Pubitemid 40524615)
7. Mesenchymal stromal cells alone or expressing interferon-beta suppress pancreatic tumors in vivo, an effect countered by anti-inflammatory treatment. Kidd S, Caldwell L, Dietrich M, Samudio I, Spaeth EL, Watson K, Shi Y, Abbruzzese J, Konopleva M, Marini FC, Cytotherapy 2010 20230221
8. Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model. Nakamura K, Ito Y, Kawano Y, Kurozumi K, Kobune M, Tsuda H, Bizen A, Honmou O, Niitsu Y, Hamada H, Gene Therapy 2004 11 1155 1164 10.1038/sj.gt.3302276 15141157 (Pubitemid 39117311)
9. Marrow stromal cells for interleukin-2 delivery in cancer immunotherapy. Stagg J, Lejeune L, Paquin A, Galipeau J, Hum Gene Ther 2004 15 597 608 10.1089/104303404323142042 15212718 (Pubitemid 41071207)
10. Neo-organoid of marrow mesenchymal stromal cells secreting interleukin-12 for breast cancer therapy. Eliopoulos N, Francois M, Boivin MN, Martineau D, Galipeau J, Cancer Res 2008 68 4810 4818 10.1158/0008-5472.CAN-08-0160 18559528
11. A tumor-selective biotherapy with prolonged impact on established metastases based on cytokine gene-engineered MSCs. Chen X, Lin X, Zhao J, Shi W, Zhang H, Wang Y, Kan B, Du L, Wang B, Wei Y, Liu Y, Zhao X, Mol Ther 2008 16 749 756 10.1038/mt.2008.3 18362930 (Pubitemid 351426177)
12. Murine bone marrow-derived mesenchymal stem cells as vehicles for interleukin-12 gene delivery into Ewing sarcoma tumors. Duan X, Guan H, Cao Y, Kleinerman ES, Cancer 2009 115 13 22 10.1002/cncr.24013 19051291
13. Human mesenchymal stem cells overexpressing pigment epithelium-derived factor inhibit hepatocellular carcinoma in nude mice. Gao Y, Yao A, Zhang W, Lu S, Yu Y, Deng L, Yin A, Xia Y, Sun B, Wang X, Oncogene 2010 29 2784 2794 10.1038/onc.2010.38 20190814
14. Targeted delivery of NK4 to multiple lung tumors by bone marrow-derived mesenchymal stem cells. Kanehira M, Xin H, Hoshino K, Maemondo M, Mizuguchi H, Hayakawa T, Matsumoto K, Nakamura T, Nukiwa T, Saijo Y, Cancer Gene Ther 2007 14 894 903 10.1038/sj.cgt.7701079 17693990 (Pubitemid 47557220)
15. Adipose-derived mesenchymal stem cells as stable source of tumor necrosis factor-related apoptosis-inducing ligand delivery for cancer therapy. Grisendi G, Bussolari R, Cafarelli L, Petak I, Rasini V, Veronesi E, De Santis G, Spano C, Tagliazzucchi M, Barti-Juhasz H, Scarabelli L, Bambi F, Frassoldati A, Rossi G, Casali C, Morandi U, Horwitz EM, Paolucci P, Conte P, Dominici M, Cancer Res 2010 70 3718 3729 10.1158/0008-5472.CAN-09-1865 20388793
16. Mesenchymal stem cell delivery of TRAIL can eliminate metastatic cancer. Loebinger MR, Eddaoudi A, Davies D, Janes SM, Cancer Res 2009 69 4134 4142 10.1158/0008-5472.CAN-08-4698 19435900
17. Mesenchymal stem cells expressing TRAIL lead to tumour growth inhibition in an experimental lung cancer model. Mohr A, Lyons M, Deedigan L, Harte T, Shaw G, Howard L, Barry F, O'Brien T, Zwacka R, J Cell Mol Med 2008 12 2628 2643 10.1111/j.1582-4934.2008.00317.x 18373740
18. Gene therapy using TRAIL-secreting human umbilical cord bloodderived mesenchymal stem cells against intracranial glioma. Kim SM, Lim JY, Park SI, Jeong CH, Oh JH, Jeong M, Oh W, Park SH, Sung YC, Jeun SS, Cancer Res 2008 68 9614 9623 10.1158/0008-5472.CAN-08-0451 19047138
19. Retroviral vector-producing mesenchymal stem cells for targeted suicide cancer gene therapy. Uchibori R, Okada T, Ito T, Urabe M, Mizukami H, Kume A, Ozawa K, J Gene Med 2009 11 373 381 10.1002/jgm.1313 19274675
20. HSV-tk expressing mesenchymal stem cells exert bystander effect on human glioblastoma cells. Matuskova M, Hlubinova K, Pastorakova A, Hunakova L, Altanerova V, Altaner C, Kucerova L, Cancer Lett 2010 290 58 67 10.1016/j.canlet.2009.08.028 19765892
21. Targeting tumor stroma using engineered mesenchymal stem cells reduces the growth of pancreatic carcinoma. Zischek C, Niess H, Ischenko I, Conrad C, Huss R, Jauch KW, Nelson PJ, Bruns C, Ann Surg 2009 250 747 753 10.1097/SLA.0b013e3181bd62d0 19826249
22. Adipose tissue-derived human mesenchymal stem cells mediated prodrug cancer gene therapy. Kucerova L, Altanerova V, Matuskova M, Tyciakova S, Altaner C, Cancer Res 2007 67 6304 6313 10.1158/0008-5472.CAN-06-4024 17616689 (Pubitemid 47037513)
23. Reduction of nontarget infection and systemic toxicity by targeted delivery of conditionally replicating viruses transported in mesenchymal stem cells. Dembinski JL, Spaeth EL, Fueyo J, Gomez-Manzano C, Studeny M, Andreeff M, Marini FC, Cancer Gene Ther 2010 17 289 297 10.1038/cgt.2009.67 19876078
24. Human mesenchymal stem cells lack tumor tropism but enhance the antitumor activity of oncolytic adenoviruses in orthotopic lung and breast tumors. Hakkarainen T, Sarkioja M, Lehenkari P, Miettinen S, Ylikomi T, Suuronen R, Desmond RA, Kanerva A, Hemminki A, Hum Gene Ther 2007 18 627 641 10.1089/hum.2007.034 17604566 (Pubitemid 47187094)
25. Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses. Komarova S, Kawakami Y, Stoff -Khalili MA, Curiel DT, Pereboeva L, Mol Cancer Ther 2006 5 755 766 10.1158/1535-7163.MCT-05-0334 16546991
26. Therapeutic potential of the immunomodulatory activities of adult mesenchymal stem cells. Petrie Aronin CE, Tuan RS, Birth Defects Res C Embryo Today 2010 90 67 74 10.1002/bdrc.20174 20301222
27. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Djouad F, Plence P, Bony C, Tropel P, Apparailly F, Sany J, Noel D, Jorgensen C, Blood 2003 102 3837 3844 10.1182/blood-2003-04-1193 12881305 (Pubitemid 37409409)
28. Earlier onset of syngeneic tumors in the presence of mesenchymal stem cells. Djouad F, Bony C, Apparailly F, Louis-Plence P, Jorgensen C, Noel D, Transplantation 2006 82 1060 1066 10.1097/01.tp.0000236098.13804.0b 17060855 (Pubitemid 44632122)
29. Mesenchymal progenitor cell-mediated inhibition of tumor growth in vivo and in vitro in gelatin matrix. Ohlsson LB, Varas L, Kjellman C, Edvardsen K, Lindvall M, Exp Mol Pathol 2003 75 248 255 10.1016/j.yexmp.2003.06.001 14611816 (Pubitemid 37373711)
30. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Le Blanc K, Tammik L, Sundberg B, Haynesworth SE, Ringden O, Scand J Immunol 2003 57 11 20 10.1046/j.1365-3083.2003.01176.x 12542793 (Pubitemid 38019084)
31. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. Dvorak HF, N Engl J Med 1986 315 1650 1659 10.1056/NEJM198612253152606 3537791 (Pubitemid 17052899)
32. Review of mesenchymal stem cells and tumors: executioner or coconspirator? Feng B, Chen L, Cancer Biother Radiopharm 2009 24 717 721 10.1089/cbr.2009.0652 20025552
33. Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Nakamizo A, Marini F, Amano T, Khan A, Studeny M, Gumin J, Chen J, Hentschel S, Vecil G, Dembinski J, Lang FF, Cancer Res 2005 65 3307 3318 15833864 (Pubitemid 40524615)
34. Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model. Nakamura K, Ito Y, Kawano Y, Kurozumi K, Kobune M, Tsuda H, Bizen A, Honmou O, Niitsu Y, Hamada H, Gene Ther 2004 11 1155 1164 10.1038/sj.gt.3302276 15141157 (Pubitemid 39117311)
35. Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. Studeny M, Marini FC, Dembinski JL, Zompetta C, Cabreira-Hansen M, Bekele BN, Champlin RE, Andreeff M, J Natl Cancer Inst 2004 96 1593 1603 10.1093/jnci/djh299 15523088 (Pubitemid 39534883)
36. Migratory neighbors and distant invaders: tumor-associated niche cells. Wels J, Kaplan RN, Rafii S, Lyden D, Genes Dev 2008 22 559 574 10.1101/gad.1636908 18316475 (Pubitemid 351342429)
37. Monocyte chemotactic protein-1 (MCP-1) secreted by primary breast tumors stimulates migration of mesenchymal stem cells (MSCs). Dwyer RM, Potter-Beirne SM, Harrington KA, Lowery AJ, Hennessy E, Murphy JM, Barry FP, O'Brien T, Kerin MJ, Clin Cancer Res 2007 13 5020 5027 10.1158/1078-0432.CCR-07-0731 17785552 (Pubitemid 47502066)
38. Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. Chamberlain G, Fox J, Ashton B, Middleton J, Stem Cells 2007 25 2739 2749 10.1634/stemcells.2007- 0197 17656645 (Pubitemid 350127858)
39. Mesenchymal stem cells display coordinated rolling and adhesion behavior on endothelial cells. Ruster B, Gottig S, Ludwig RJ, Bistrian R, Muller S, Seifried E, Gille J, Henschler R, Blood 2006 108 3938 3944 10.1182/blood-2006- 05-025098 16896152 (Pubitemid 44864580)
40. Towards in situ tissue repair: human mesenchymal stem cells express chemokine receptors CXCR1, CXCR2 and CCR2, and migrate upon stimulation with CXCL8 but not CCL2. Ringe J, Strassburg S, Neumann K, Endres M, Notter M, Burmester GR, Kaps C, Sittinger M, J Cell Biochem 2007 101 135 146 10.1002/jcb.21172 17295203 (Pubitemid 46652579)
41. Human bone marrow stromal cells express a distinct set of biologically functional chemokine receptors. Honczarenko M, Le Y, Swierkowski M, Ghiran I, Glodek AM, Silberstein LE, Stem Cells 2006 24 1030 1041 10.1634/stemcells.2005- 0319 16253981 (Pubitemid 44464736)
42. Human adult CD34-progenitor cells functionally express the chemokine receptors CCR1, CCR4, CCR7, CXCR5, and CCR10 but not CXCR4. Von Luttichau I, Notohamiprodjo M, Wechselberger A, Peters C, Henger A, Seliger C, Djafarzadeh R, Huss R, Nelson PJ, Stem Cells Dev 2005 14 329 336 10.1089/scd.2005.14.329 15969628 (Pubitemid 40885257)
43. Bone marrow mesenchymal stem cells express a restricted set of functionally active chemokine receptors capable of promoting migration to pancreatic islets. Sordi V, Malosio ML, Marchesi F, Mercalli A, Melzi R, Giordano T, Belmonte N, Ferrari G, Leone BE, Bertuzzi F, Zerbini G, Allavena P, Bonifacio E, Piemonti L, Blood 2005 106 419 427 10.1182/blood-2004-09-3507 15784733 (Pubitemid 40981232)
44. Murine mesenchymal stem cells exhibit a restricted repertoire of functional chemokine receptors: comparison with human. Chamberlain G, Wright K, Rot A, Ashton B, Middleton J, PLoS One 2008 3 2934 10.1371/journal.pone.0002934 18698345
45. Regulation of CXCR4 expression in human mesenchymal stem cells by cytokine treatment: role in homing efficiency in NOD/SCID mice. Shi M, Li J, Liao L, Chen B, Li B, Chen L, Jia H, Zhao RC, Haematologica 2007 92 897 904 10.3324/haematol.10669 17606439 (Pubitemid 350144236)
46. A small proportion of mesenchymal stem cells strongly expresses functionally active CXCR4 receptor capable of promoting migration to bone marrow. Wynn RF, Hart CA, Corradi-Perini C, O'Neill L, Evans CA, Wraith JE, Fairbairn LJ, Bellantuono I, Blood 2004 104 2643 2645 10.1182/blood-2004-02-0526 15251986 (Pubitemid 39434942)
47. Culturing of human mesenchymal stem cells as three-dimensional aggregates induces functional expression of CXCR4 that regulates adhesion to endothelial cells. Potapova IA, Brink PR, Cohen IS, Doronin SV, J Biol Chem 2008 283 13100 13107 10.1074/jbc.M800184200 18334485
48. Radiation increases invasion of genemodified mesenchymal stem cells into tumors. Zielske SP, Livant DL, Lawrence TS, Int J Radiat Oncol Biol Phys 2009 75 843 853 10.1016/j.ijrobp.2008.06.1953 18849123
49. Tumor irradiation increases the recruitment of circulating mesenchymal stem cells into the tumor microenvironment. Klopp AH, Spaeth EL, Dembinski JL, Woodward WA, Munshi A, Meyn RE, Cox JD, Andreeff M, Marini FC, Cancer Res 2007 67 11687 11695 10.1158/0008-5472.CAN-07-1406 18089798
50. Inflammation and cancer. Coussens LM, Werb Z, Nature 2002 420 860 867 10.1038/nature01322 12490959 (Pubitemid 36019639)
51. Engineered mesenchymal stem cells with self-assembled vesicles for systemic cell targeting. Sarkar D, Vemula PK, Zhao W, Gupta A, Karnik R, Karp JM, Biomaterials 2010 31 5266 5274 10.1016/j.biomaterials.2010.03.006 20381141
52. Epidermal growth factor receptor-transfected bone marrow stromal cells exhibit enhanced migratory response and therapeutic potential against murine brain tumors. Sato H, Kuwashima N, Sakaida T, Hatano M, Dusak JE, Fellows-Mayle WK, Papworth GD, Watkins SC, Gambotto A, Pollack IF, Okada H, Cancer Gene Ther 2005 12 757 768 10.1038/sj.cgt.7700827 15832173 (Pubitemid 41208615)
53. Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy. Sasportas LS, Kasmieh R, Wakimoto H, Hingtgen S, van de Water JA, Mohapatra G, Figueiredo JL, Martuza RL, Weissleder R, Shah K, Proc Natl Acad Sci USA 2009 106 4822 4827 10.1073/pnas.0806647106 19264968
54. Mesenchymal stem cells effectively deliver an oncolytic adenovirus to intracranial glioma. Sonabend AM, Ulasov IV, Tyler MA, Rivera AA, Mathis JM, Lesniak MS, Stem Cells 2008 26 831 841 10.1634/stemcells.2007-0758 18192232
55. Mesenchymal stem cells as a vehicle for targeted delivery of CRAds to lung metastases of breast carcinoma. Stoff -Khalili MA, Rivera AA, Mathis JM, Banerjee NS, Moon AS, Hess A, Rocconi RP, Numnum TM, Everts M, Chow LT, Douglas JT, Siegal GP, Zhu ZB, Bender HG, Dall P, Stoff A, Pereboeva L, Curiel DT, Breast Cancer Res Treat 2007 105 157 167 10.1007/s10549-006-9449-8 17221158 (Pubitemid 47366887)
56. Approaches to utilize mesenchymal progenitor cells as cellular vehicles. Pereboeva L, Komarova S, Mikheeva G, Krasnykh V, Curiel DT, Stem Cells 2003 21 389 404 10.1634/stemcells.21-4-389 12832693 (Pubitemid 36793483)
57. Spontaneous human adult stem cell transformation. Rubio D, Garcia-Castro J, Martin MC, de la Fuente R, Cigudosa JC, Lloyd AC, Bernad A, Cancer Res 2005 65 3035 3039 15833829 (Pubitemid 40524580)
58. Outgrowth of a transformed cell population derived from normal human BM mesenchymal stem cell culture. Wang Y, Huso DL, Harrington J, Kellner J, Jeong DK, Turney J, McNiece IK, Cytotherapy 2005 7 509 519 10.1080/14653240500363216 16306013 (Pubitemid 43078081)
59. Human bone marrow derived mesenchymal stem cells do not undergo transformation after long-term in vitro culture and do not exhibit telomere maintenance mechanisms. Bernardo ME, Zaff aroni N, Novara F, Cometa AM, Avanzini MA, Moretta A, Montagna D, Maccario R, Villa R, Daidone MG, Zuffardi O, Locatelli F, Cancer Res 2007 67 9142 9149 10.1158/0008-5472.CAN-06-4690 17909019 (Pubitemid 47535900)
60. Spontaneous transformation of cultured mouse bone marrow-derived stromal cells. Zhou YF, Bosch-Marce M, Okuyama H, Krishnamachary B, Kimura H, Zhang L, Huso DL, Semenza GL, Cancer Res 2006 66 10849 10854 10.1158/0008-5472.CAN-06- 2146 17108121 (Pubitemid 44876981)
61. Accumulated chromosomal instability in murine bone marrow mesenchymal stem cells leads to malignant transformation. Miura M, Miura Y, Padilla-Nash HM, Molinolo AA, Fu B, Patel V, Seo BM, Sonoyama W, Zheng JJ, Baker CC, Chen W, Ried T, Shi S, Stem Cells 2006 24 1095 1103 10.1634/stemcells.2005-0403 16282438 (Pubitemid 44464742)
62. Sarcoma derived from cultured mesenchymal stem cells. Tolar J, Nauta AJ, Osborn MJ, Panoskaltsis Mortari A, McElmurry RT, Bell S, Xia L, Zhou N, Riddle M, Schroeder TM, Westendorf JJ, McIvor RS, Hogendoorn PC, Szuhai K, Oseth L, Hirsch B, Yant SR, Kay MA, Peister A, Prockop DJ, Fibbe WE, Blazar BR, Stem Cells 2007 25 371 379 10.1634/stemcells.2005-0620 17038675 (Pubitemid 46232791)
63. Spontaneous expression of embryonic factors and p53 point mutations in aged mesenchymal stem cells: a model of age-related tumorigenesis in mice. Li H, Fan X, Kovi RC, Jo Y, Moquin B, Konz R, Stoicov C, Kurt-Jones E, Grossman SR, Lyle S, Rogers AB, Montrose M, Houghton J, Cancer Res 2007 67 10889 10898 10.1158/0008-5472.CAN-07-2665 18006834 (Pubitemid 350145918)
64. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, Richardson AL, Polyak K, Tubo R, Weinberg RA, Nature 2007 449 557 563 10.1038/nature06188 17914389 (Pubitemid 47525152)
65. Tissue-resident stem cells promote breast cancer growth and metastasis. Muehlberg FL, Song YH, Krohn A, Pinilla SP, Droll LH, Leng X, Seidensticker M, Ricke J, Altman AM, Devarajan E, Liu W, Arlinghaus RB, Alt EU, Carcinogenesis 2009 30 589 597 10.1093/carcin/bgp036 19181699
66. Adult human mesenchymal stem cells enhance breast tumorigenesis and promote hormone independence. Rhodes LV, Muir SE, Elliott S, Guillot LM, Antoon JW, Penfornis P, Tilghman SL, Salvo VA, Fonseca JP, Lacey MR, Beckman BS, McLachlan JA, Rowan BG, Pochampally R, Burow ME, Breast Cancer Res Treat 2010 121 293 300 10.1007/s10549-009-0458-2 19597705
67. Mesenchymal stem cells share molecular signature with mesenchymal tumor cells and favor early tumor growth in syngeneic mice. Galie M, Konstantinidou G, Peroni D, Scambi I, Marchini C, Lisi V, Krampera M, Magnani P, Merigo F, Montani M, Boschi F, Marzola P, Orru R, Farace P, Sbarbati A, Amici A, Oncogene 2008 27 2542 2551 10.1038/sj.onc.1210920 17998939 (Pubitemid 351550885)
68. Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. Spaeth EL, Dembinski JL, Sasser AK, Watson K, Klopp A, Hall B, Andreeff M, Marini F, PloS one 2009 4 4992 10.1371/journal.pone.0004992 19352430
69. Bone marrow multipotent mesenchymal stroma cells act as pericyte-like migratory vehicles in experimental gliomas. Bexell D, Gunnarsson S, Tormin A, Darabi A, Gisselsson D, Roybon L, Scheding S, Bengzon J, Mol Ther 2009 17 183 190 10.1038/mt.2008.229 18985030
70. Mesenchymal stem cells derived from human adipose tissues favor tumor cell growth in vivo. Yu JM, Jun ES, Bae YC, Jung JS, Stem Cells Dev 2008 17 463 473 10.1089/scd.2007.0181 18522494 (Pubitemid 351948199)
71. Mesenchymal stem cells enhance growth and metastasis of colon cancer. Shinagawa K, Kitadai Y, Tanaka M, Sumida T, Kodama M, Higashi Y, Tanaka S, Yasui W, Chayama K, Int J Cancer 2010 20473928
72. Mesenchymal stem cells derived from bone marrow favor tumor cell growth in vivo. Zhu W, Xu W, Jiang R, Qian H, Chen M, Hu J, Cao W, Han C, Chen Y, Exp Mol Pathol 2006 80 267 274 10.1016/j.yexmp.2005.07.004 16214129
73. Bone marrow-derived stem cells in wound healing: a review. Wu Y, Wang J, Scott PG, Tredget EE, Wound Repair Regen 2007 15 Suppl 1 18 S26 10.1111/j.1524-475X.2007.00221.x 17727462 (Pubitemid 47301670)
74. Mesenchymal stem cells enhance wound healing through differentiation and angiogenesis. Wu Y, Chen L, Scott PG, Tredget EE, Stem Cells 2007 25 2648 2659 10.1634/stemcells.2007-0226 17615264 (Pubitemid 47582758)
75. Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells. Mishra PJ, Mishra PJ, Humeniuk R, Medina DJ, Alexe G, Mesirov JP, Ganesan S, Glod JW, Banerjee D, Cancer Res 2008 68 4331 4339 10.1158/0008-5472.CAN-08-0943 18519693
76. Human mesenchymal stem cells from bone marrow express tumor endothelial and stromal markers. Bagley RG, Weber W, Rouleau C, Yao M, Honma N, Kataoka S, Ishida I, Roberts BL, Teicher BA, Int J Oncol 2009 34 619 627 10.3892/ijo-00000187 19212666
77. Suppression of tumorigenesis by human mesenchymal stem cells in a hepatoma model. Qiao L, Xu Z, Zhao T, Zhao Z, Shi M, Zhao RC, Ye L, Zhang X, Cell Res 2008 18 500 507 10.1038/cr.2008.40 18364678 (Pubitemid 351498857)
78. Factor(s) from nonmacrophage bone marrow stromal cells inhibit Lewis lung carcinoma and B16 melanoma growth in mice. Maestroni GJ, Hertens E, Galli P, Cell Mol Life Sci 1999 55 663 667 10.1007/s000180050322 10357234 (Pubitemid 29221598)
79. Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma. Khakoo AY, Pati S, Anderson SA, Reid W, Elshal MF, Nguyen AT, Malide D, Combs CA, Hall G, Zhang J, Raffeld M, Rogers TB, Stetler-Stevenson W, Frank JA, Reitz M, Finkel T, J Exp Med 2006 203 1235 1247 10.1084/jem.20051921 16636132